vTv Therapeutics (VTVT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Jun, 2026Opening remarks and agenda
Meeting called to order at 11:00 A.M. with appreciation expressed to virtual attendees.
Stockholders of record as of April 14, 2026, were notified and provided access to proxy materials and annual report.
Introduction of meeting participants, including the Secretary and Inspector of Election.
Confirmation of proper notice and availability of stockholder list for voting.
Approximately 3.9 million shares entitled to vote, with a quorum established by 2.9 million shares represented.
Board and executive committee updates
Seven directors were nominated for election to the board.
Shareholder proposals
Stockholders voted on three matters: election of directors, ratification of the independent auditor, and advisory approval of executive compensation.
Latest events from vTv Therapeutics
- Phase III oral therapy for T1D nears enrollment completion, targeting major unmet need.VTVT
38th Annual Roth Conference15 Jun 2026 - Phase III oral therapy for T1D targets hypoglycemia and A1C reduction, data due year-end.VTVT
TD Cowen 46th Annual Health Care Conference13 Jun 2026 - Stockholders will vote on directors, auditor ratification, and executive compensation at the rescheduled meeting.VTVT
Proxy filing10 Jun 2026 - Cash surged from $51M financing, but pivotal diabetes trial remains on FDA clinical hold.VTVT
Q2 20243 Jun 2026 - Net loss narrowed and cash position improved, but FDA hold delays lead diabetes program.VTVT
Q3 20243 Jun 2026 - FDA lifts clinical hold, Phase 3 diabetes trial resumes Q2 2025; cash rises, net loss narrows.VTVT
Q4 20243 Jun 2026 - Q1 net loss $5.1M, cash $31.1M, expedited Phase 3 trial, ongoing funding risk.VTVT
Q1 20251 Jun 2026 - Net loss rose to $6.0M in Q2 2025 as Phase 3 cadisegliatin trial began and cash declined.VTVT
Q2 20251 Jun 2026 - Net loss rose to $8.7M, cash reached $98.5M, and pivotal trial data expected in H2 2026.VTVT
Q3 20251 Jun 2026